MetaCap

Agenus (AGEN) vs Lexeo Therapeutics (LXEO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Agenus (AGEN) has outperformed Lexeo Therapeutics (LXEO) over the past year, gaining 41.5% versus a loss of 67.3%. Agenus is the larger company by market cap ($270.1 million vs $245.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGEN+41.47%LXEO-67.33%
+146%+32%-81%
Nov 21, 20251 yearNov 20, 2026
AGEN-64.46%LXEO-70.55%
+83%-8%-99%
Oct 30, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGEN versus LXEO key metrics
MetricAGENLXEO
Share price$5.97$2.96
Market cap$270.12M$245.05M
1-day change-2.77%+0.34%
YTD return+90.13%-70.19%
1-year return+41.47%-67.33%
5-year return-90.58%—
P/E ratio (TTM)25.96—
EPS (TTM)$0.23$-1.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$114.20M—
Revenue growth (YoY)+10.37%—
Net income (latest FY)$-3.08M$-100.00M
Gross margin99.11%—
Operating margin-17.66%—
Net margin-2.70%—
52-week high$10.31$10.99
52-week low$2.71$2.55
Distance from 52-week high-42.10%-73.07%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+352.26%+748.31%
Average volume905.17K1.98M
Shares outstanding45.25M82.79M
Employees8168
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AGEN has outperformed LXEO by 108.8 percentage points over the past year.

About Agenus

AGEN stock →

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About Lexeo Therapeutics

LXEO stock →

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees

AGEN vs LXEO FAQ

Which is bigger, Agenus or Lexeo Therapeutics?

Agenus (AGEN) is larger, with a market capitalization of $270.12M compared with $245.05M for Lexeo Therapeutics (LXEO).

Which stock has performed better over the past year, AGEN or LXEO?

AGEN returned +41.47% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.

Are Agenus and Lexeo Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons